Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific InnovationGlobeNewsWire • 01/04/23
Certara Announces the Completion of Arsenal Capital Partners' Investment and the Appointment of David Spaight to the Board of DirectorsGlobeNewsWire • 12/08/22
Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock PurchaseGlobeNewsWire • 11/07/22
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara's Software for Evaluating Regulatory SubmissionsGlobeNewsWire • 10/19/22
Certara, Inc. (CERT) CEO William Feehery on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange ModuleGlobeNewsWire • 08/05/22
Certara Announces Collaboration with Leading Cancer Center to Advance CAR T-cell TherapiesGlobeNewsWire • 07/28/22
Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug DevelopmentGlobeNewsWire • 06/28/22
Certara Announces New Versions of Biosimulation Software for Development of Novel BiologicsGlobeNewsWire • 06/21/22
Certara, Inc.'s (CERT) CEO William Feehery on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/08/22